Detalhe da pesquisa
1.
Atezolizumab Plus Carboplatin and Etoposide in Patients with Untreated Extensive-Stage Small-Cell Lung Cancer: Interim Results of the MAURIS Phase IIIb Trial.
Oncologist
; 29(5): e690-e698, 2024 May 03.
Artigo
Inglês
| MEDLINE | ID: mdl-38377176
2.
Therapeutical Options in ROS1-Rearranged Advanced Non Small Cell Lung Cancer.
Int J Mol Sci
; 24(14)2023 Jul 15.
Artigo
Inglês
| MEDLINE | ID: mdl-37511255
3.
Liquid Biopsy in NSCLC: An Investigation with Multiple Clinical Implications.
Int J Mol Sci
; 24(13)2023 Jun 28.
Artigo
Inglês
| MEDLINE | ID: mdl-37445976
4.
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial.
Lancet Oncol
; 23(4): 540-552, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35358455
5.
NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease.
Int J Mol Sci
; 23(12)2022 Jun 17.
Artigo
Inglês
| MEDLINE | ID: mdl-35743191
6.
Targeted Therapy and Immunotherapy in Early-Stage Non-Small Cell Lung Cancer: Current Evidence and Ongoing Trials.
Int J Mol Sci
; 23(13)2022 Jun 29.
Artigo
Inglês
| MEDLINE | ID: mdl-35806230
7.
Bone Metastasis and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (NSCLC): Microenvironment and Possible Clinical Implications.
Int J Mol Sci
; 23(12)2022 Jun 20.
Artigo
Inglês
| MEDLINE | ID: mdl-35743275
8.
Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
Int J Mol Sci
; 23(13)2022 Jun 22.
Artigo
Inglês
| MEDLINE | ID: mdl-35805940
9.
The Change in Paradigm for NSCLC Patients with EML4-ALK Translocation.
Int J Mol Sci
; 23(13)2022 Jun 30.
Artigo
Inglês
| MEDLINE | ID: mdl-35806325
10.
Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era.
Int J Mol Sci
; 23(12)2022 Jun 09.
Artigo
Inglês
| MEDLINE | ID: mdl-35742920
11.
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial.
Oncologist
; 26(9): 740-750, 2021 09.
Artigo
Inglês
| MEDLINE | ID: mdl-34077597
12.
Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 379(21): 2027-2039, 2018 11 22.
Artigo
Inglês
| MEDLINE | ID: mdl-30280657
13.
Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
Oncology
; 99(12): 747-755, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34583356
14.
Is multidisciplinary management possible in the treatment of lung cancer? A report from three Italian meetings.
Radiol Med
; 125(2): 214-219, 2020 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-31605353
15.
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
BJU Int
; 123(1): 98-105, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-29956884
16.
NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet Oncol
; 19(6): 799-811, 2018 06.
Artigo
Inglês
| MEDLINE | ID: mdl-29753703
17.
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Lancet Oncol
; 19(12): 1654-1667, 2018 12.
Artigo
Inglês
| MEDLINE | ID: mdl-30413378
18.
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.
Future Oncol
; 14(4): 353-361, 2018 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-29135281
19.
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 18(7): 874-886, 2017 07.
Artigo
Inglês
| MEDLINE | ID: mdl-28602779
20.
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Lancet Oncol
; 18(9): 1261-1273, 2017 09.
Artigo
Inglês
| MEDLINE | ID: mdl-28729154